Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview
Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
100B
P/E Ratio
18.10
EPS (TTM)
N/A
ROE
0.32%
CELG-RI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company Ce (CELG-RI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.07, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.10 and a market capitalization of 100B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.